RecruitingNCT06865482
Clinical Course Of Disease In Participants With FA-CM
Characteristics And Clinical Course Of Disease In Participants With Cardiomyopathy Associated With Friedreich Ataxia (CLARITY-FA)
Sponsor
Lexeo Therapeutics
Enrollment
65 participants
Start Date
Sep 30, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)
Eligibility
Min Age: 6 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with cardiomyopathy and friedreich ataxia. The study is currently recruiting participants at 14 locations. People eligible for this study include aged 6 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(19)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06865482
Related Trials
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
NCT077210251 location
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
NCT011434543 locations
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
NCT066286871 location
A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
NCT071165256 locations
Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)
NCT075418331 location